Evidence map›Paper›PMID 28105753›Full record

ArticleHematological oncology2017

Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.

Li-Wen Huang, Wendi Bacon, Constance Cirrincione, Bercedis Peterson, Gwynn Long, David Rizzieri, Keith M Sullivan, Kelly Corbet, Mitchell Horwitz, Nelson Chao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematological oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Li-Wen HuangDepartment of Internal Medicine, Duke University Medical Center, Durham, NC, USA.
Wendi BaconDivision of Hematological Malignancies and Cellular Therapy, Duke Cancer Institute, Durham, NC, USA.
Constance CirrincioneDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.
Bercedis PetersonDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.
Gwynn LongDepartment of Internal Medicine, Duke University Medical Center, Durham, NC, USA.
David RizzieriDepartment of Internal Medicine, Duke University Medical Center, Durham, NC, USA.
Keith M SullivanDepartment of Internal Medicine, Duke University Medical Center, Durham, NC, USA.
Kelly CorbetDepartment of Internal Medicine, Duke University Medical Center, Durham, NC, USA.
Mitchell HorwitzDepartment of Internal Medicine, Duke University Medical Center, Durham, NC, USA.
Nelson ChaoDepartment of Internal Medicine, Duke University Medical Center, Durham, NC, USA.
Cristina GasparettoDepartment of Internal Medicine, Duke University Medical Center, Durham, NC, USA.
Sascha A TuchmanDepartment of Internal Medicine, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0003-2109-1573

Funding

RESEARCH TRAINING IN GERIATRIC MEDICINET32AG000212 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alexander Keliimoeanu Smith · 1991 to 2026
$7.7M
NIA NIH HHS T32 AG000212
6 · The paper itself

Abstract

We retrospectively studied 340 fit patients with multiple myeloma (MM) who underwent autologous stem cell transplantation (ASCT). We hypothesized that progression-free survival (PFS) of older patients was non-inferior to that of younger patients after ASCT. Our null hypothesis was that the PFS hazard ratio (HR) for a 5-year increase in age was ≥1.05; the alternative (non-inferiority) hypothesis was that the HR was ≤1. The observed HR was 0.94 (95% confidence interval [CI] 0.86-1.03); since the CI upper bound was <1.05, we reject the null hypothesis and conclude that PFS in older patients was at least as good as in younger patients. We cannot reject an analogous null hypothesis for overall survival (HR 1.06 [95% CI 0.94-1.19]), since the CI upper bound >1.05. Toxicity was similar across ages and transplant-related mortality was minimal. 28% of subjects <65 versus 45% of those ≥65 received maintenance therapy. In summary, ASCT prolongs PFS equally well in older vs. younger adults. Although we cannot exclude maintenance as a confounder, these data support ASCT for fit seniors with MM.

Indexed as

Age FactorsFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedMultiple MyelomaRetrospective StudiesSurvival RateTransplantation, AutologousTransplantation Conditioningautologouschemotherapyelderlymyelomaseniortransplantation

Identifiers

PMID28105753
PMCPMC5949235

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.